Skip to main content
eScholarship
Open Access Publications from the University of California

Screening for von Hippel-Lindau disease by DNA polymorphism analysis.

  • Author(s): Glenn, GM
  • Linehan, WM
  • Hosoe, S
  • Latif, F
  • Yao, M
  • Choyke, P
  • Gorin, MB
  • Chew, E
  • Olfield, E
  • Manolatos, C
  • et al.
Abstract

OBJECTIVE:Von Hippel-Lindau (VHL) disease is a rare, inherited multisystem neoplastic disorder. There is no biochemical test available to distinguish VHL disease gene carriers from their healthy siblings. We evaluated DNA polymorphism analysis as a method for identifying disease gene carriers. DESIGN:Prospective comparison of the results of DNA analysis with a comprehensive clinical screening examination. SETTING:The Clinical Center of the National Institutes of Health. PATIENTS:Blood was collected from 182 members of 16 families with VHL disease. Forty-eight asymptomatic individuals, at risk of developing this hereditary illness (with an affected parent or sibling), were examined for occult disease at the Clinical Center of the National Institutes of Health and tested by DNA polymorphism analysis. RESULTS:DNA polymorphism analysis predicted nine disease gene carriers and 33 individuals with the wild-type (normal) allele among the 48 individuals at risk of developing VHL disease; the test was not informative in six individuals. All nine individuals predicted to carry the VHL gene had evidence of occult disease on clinical examination. There was no clinical evidence of VHL disease in 32 of 33 individuals predicted to carry the wild-type allele. CONCLUSIONS:DNA polymorphism analysis can identify individuals likely to carry the VHL disease gene among asymptomatic members of disease families. This technique serves to focus attention on those individuals who require periodic medical examination and may help to alleviate the morbidity and mortality associated with this disease.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View